Irritable bowel syndrome gains new treatment
Amitiza has gained a new indication-to treat irritable bowel syndrome with constipation in women.
Amitiza (lubiprostone), formerly approved to treat chronic idiopathic constipation, has gained clearance for a new indication. The drug can now be used to treat irritable bowel syndrome with constipation (IBS-C) in adult women. According to Sucampo Pharmaceuticals and Takeda Pharmaceuticals America, the product is the only approved treatment for IBS-C in this country.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
